Von Willebrand factor and ADAMTS13 in arterial thrombosis: A systematic review and meta-analysis

Blood Reviews

Volumn 28, Issue 4, 2014, Pages 167-178

  Sonneveld, Michelle A H ^a   De Maat, Moniek P M ^a   Leebeek, Frank W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ADAMTS13; Coronary heart disease; Ischemic stroke; Myocardial infarction; Von Willebrand factor

Indexed keywords

RECOMBINANT ENZYME; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CASE CONTROL STUDY; ENZYME ASSAY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANIMAL; ARTERY; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE MODEL; GENETICS; META ANALYSIS; METABOLISM; MOUSE; PATHOLOGY; THROMBOSIS; VON WILLEBRAND DISEASE;

ADAM PROTEINS; ANIMALS; ARTERIES; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MICE; THROMBOSIS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84903199139     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.04.003     Document Type: Article

References (161)

1. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997, 96(4):1102-1108.
2. Folsom A.R., Rosamond W.D., Shahar E., Cooper L.S., Aleksic N., Nieto F.J., et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999, 100(7):736-742.
3. Cortellaro M., Boschetti C., Cofrancesco E., Zanussi C., Catalano M., de Gaetano G., et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb 1992, 12(9):1063-1070. [Clinical Trial Multicenter Study Research Support, Non-U.S. Gov't].
4. Smith F.B., Lee A.J., Fowkes F.G., Price J.F., Rumley A., Lowe G.D. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997, 17(11):3321-3325.
5. Ruggeri Z.M. The role of von Willebrand factor in thrombus formation. Thromb Res 2007, 120(Suppl. 1):S5-S9.
6. Gerritsen H.E., Robles R., Lammle B., Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001, 98(6):1654-1661.
7. Fujikawa K., Suzuki H., McMullen B., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001, 98(6):1662-1666.
8. Brinkhous K.M., Sandberg H., Garris J.B., Mattsson C., Palm M., Griggs T., et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985, 82(24):8752-8756. [Research Support, U.S. Gov't, P.H.S.].
9. De Meyer S.F., Deckmyn H., Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009, 113(21):5049-5057. [Review].
10. Rodeghiero F., Castaman G., Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987, 69(2):454-459. [Research Support, Non-U.S. Gov't].
11. Ginsburg D., Handin R.I., Bonthron D.T., Donlon T.A., Bruns G.A., Latt S.A., et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985, 228(4706):1401-1406.
12. Lynch D.C., Zimmerman T.S., Collins C.J., Brown M., Morin M.J., Ling E.H., et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 1985, 41(1):49-56.
13. Sadler J.E., Shelton-Inloes B.B., Sorace J.M., Harlan J.M., Titani K., Davie E.W. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A 1985, 82(19):6394-6398.
14. Verweij C.L., de Vries C.J., Distel B., van Zonneveld A.J., van Kessel A.G., van Mourik J.A., et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res 1985, 13(13):4699-4717.
15. Gill J.C., Endres-Brooks J., Bauer P.J., Marks W.J., Montgomery R.R. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987, 69(6):1691-1695.
16. Gallinaro L., Cattini M.G., Sztukowska M., Padrini R., Sartorello F., Pontara E., et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008, 111(7):3540-3545. [Comparative Study Research Support, Non-U.S. Gov't].
17. McGrath R.T., McRae E., Smith O.P., O'Donnell J.S. Platelet von Willebrand factor-structure, function and biological importance. Br J Haematol 2010, 148(6):834-843.
18. Vischer U.M. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006, 4(6):1186-1193.
19. Whincup P.H., Danesh J., Walker M., Lennon L., Thomson A., Appleby P., et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002, 23(22):1764-1770.
20. Willeit P., Thompson A., Aspelund T., Rumley A., Eiriksdottir G., Lowe G., et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS ONE 2013, 8(2):e55175.
21. Rumley A., Lowe G.D., Sweetnam P.M., Yarnell J.W., Ford R.P. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999, 105(1):110-116.
22. Morange P.E., Simon C., Alessi M.C., Luc G., Arveiler D., Ferrieres J., et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004, 109(11):1343-1348.
23. Wannamethee S.G., Whincup P.H., Shaper A.G., Rumley A., Lennon L., Lowe G.D. Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost 2009, 7(10):1605-1611.
24. Kucharska-Newton A.M., Couper D.J., Pankow J.S., Prineas R.J., Rea T.D., Sotoodehnia N., et al. Hemostasis, inflammation, and fatal and nonfatal coronary heart disease: long-term follow-up of the atherosclerosis risk in communities (ARIC) cohort. Arterioscler Thromb Vasc Biol 2009, 29(12):2182-2190.
25. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., Fowkes F.G. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007, 115(16):2119-2127.
26. Wennberg P., Wensley F., Di Angelantonio E., Johansson L., Boman K., Rumley A., et al. Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women. Thromb Res 2012, 129(1):68-73.
27. Kim H.C., Greenland P., Rossouw J.E., Manson J.E., Cochrane B.B., Lasser N.L., et al. Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol 2010, 55(19):2080-2091.
28. Empana J.P., Canoui-Poitrine F., Luc G., Juhan-Vague I., Morange P., Arveiler D., et al. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J 2008, 29(16):1966-1974.
29. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350(14):1387-1397.
30. Folsom A.R., Wu K.K., Shahar E., Davis C.E. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb 1993, 13(12):1829-1836.
31. Chion C.K., Doggen C.J., Crawley J.T., Lane D.A., Rosendaal F.R. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007, 109(5):1998-2000.
32. Peyvandi F., Hollestelle M.J., Palla R., Merlini P.A., Feys H.B., Vanhoorelbeke K., et al. Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. J Thromb Haemost 2010, 8(7):1653-1656.
33. Andersson H.M., Siegerink B., Luken B.M., Crawley J.T., Algra A., Lane D.A., et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012, 119(6):1555-1560.
34. Jansson J.H., Nilsson T.K., Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991, 66(5):351-355.
35. Vaziri N.D., Kennedy S.C., Kennedy D., Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992, 93(6):651-657. [Comparative Study].
36. Blann A.D., McCollum C.N. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 1999, 10(6):375-380.
37. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000, 20(8):2019-2023. [Research Support, Non-U.S. Gov't].
38. Tanis B., Algra A., van der Graaf Y., Helmerhorst F., Rosendaal F. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol 2006, 77(1):67-73. [Research Support, Non-U.S. Gov't].
39. Tousoulis D., Antoniades C., Bosinakou E., Kotsopoulou M., Tsoufis C., Marinou K., et al. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction. Int J Cardiol 2007, 115(2):203-207. [Comparative Study].
40. Matsukawa M., Kaikita K., Soejima K., Fuchigami S., Nakamura Y., Honda T., et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007, 100(5):758-763.
41. Crawley J.T., Lane D.A., Woodward M., Rumley A., Lowe G.D. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008, 6(4):583-588.
42. Horii M., Uemura S., Uemura M., Matsumoto M., Ishizashi H., Imagawa K., et al. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels 2008, 23(5):301-307. [Comparative Study Research Support, Non-U.S. Gov't].
43. Hoffmeister A., Rothenbacher D., Bazner U., Frohlich M., Brenner H., Hombach V., et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001, 87(3):262-266. [Research Support, Non-U.S. Gov't].
44. Schumacher A., Seljeflot I., Sommervoll L., Christensen B., Otterstad J.E., Arnesen H. Increased levels of endothelial haemostatic markers in patients with coronary heart disease. Thromb Res 2002, 105(1):25-31. [Research Support, Non-U.S. Gov't].
45. Miura M., Kaikita K., Matsukawa M., Soejima K., Fuchigami S., Miyazaki Y., et al. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost 2010, 103(3):623-629.
46. Bongers T.N., de Bruijne E.L., Dippel D.W., de Jong A.J., Deckers J.W., Poldermans D., et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009, 207(1):250-254.
47. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332(10):635-641. [Clinical Trial Multicenter Study Research Support, Non-U.S. Gov't].
48. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., Lip G.Y. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003, 107(25):3141-3145.
49. Ruef J., Marz W., Winkelmann B.R. Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study). Scand Cardiovasc J 2006, 40(5):274-279.
50. Meade T.W., Cooper J.A., Stirling Y., Howarth D.J., Ruddock V., Miller G.J. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994, 88(3):601-607.
51. Smith A., Patterson C., Yarnell J., Rumley A., Ben-Shlomo Y., Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005, 112(20):3080-3087.
52. May M., Lawlor D.A., Patel R., Rumley A., Lowe G., Ebrahim S. Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study. Eur J Cardiovasc Prev Rehabil 2007, 14(5):638-645.
53. Carcaillon L., Gaussem P., Ducimetiere P., Giroud M., Ritchie K., Dartigues J.F., et al. Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: the Three-City cohort study. J Thromb Haemost 2009, 7(12):1972-1978.
54. van Loon J.E., de Maat M.P., Hofman A., Witteman J.C., Leebeek F.W. Relationship between thrombospondin gene variations, von Willebrand factor levels and the risk of coronary heart disease in an older population. J Thromb Haemost 2011, 9(7):1415-1417. [Letter Research Support, Non-U.S. Gov't].
55. Kavousi M., Elias-Smale S., Rutten J.H., Leening M.J., Vliegenthart R., Verwoert G.C., et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012, 156(6):438-444.
56. Woodward M., Rumley A., Welsh P., MacMahon S., Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 2007, 5(9):1795-1800.
57. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98(21):2241-2247.
58. Hamsten A., Blomback M., Wiman B., Svensson J., Szamosi A., de Faire U., et al. Haemostatic function in myocardial infarction. Br Heart J 1986, 55(1):58-66.
59. van Loon J.E., de Maat M.P., Deckers J.W., van Domburg R.T., Leebeek F.W. Prognostic markers in young patients with premature coronary heart disease. Atherosclerosis 2012, 224(1):213-217.
60. Smith F.B., Rumley A., Lee A.J., Leng G.C., Fowkes F.G., Lowe G.D. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998, 100(4):758-763.
61. Kaikita K., Soejima K., Matsukawa M., Nakagaki T., Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 2006, 4(11):2490-2493.
62. Koprivica Z., Djordjevic D., Vuletic M., Zivkovic V., Barudzic N., Andjelkovic N., et al. Von Willebrand factor and oxidative stress parameters in acute coronary syndromes. Oxidative Med Cell Longev 2011, 918312. [Research Support, Non-U.S. Gov't].
63. Moss A.J., Goldstein R.E., Marder V.J., Sparks C.E., Oakes D., Greenberg H., et al. Thrombogenic factors and recurrent coronary events. Circulation 1999, 99(19):2517-2522.
64. Nielsen N.E., Siegbahn A., Swahn E. Markers of hypercoagulation and von Willebrand factor in postmenopausal women with unstable coronary artery disease. Discriminatory ability regarding unstable coronary artery disease and coronary atherosclerosis using receiver operating characteristics. J Intern Med 2000, 248(2):151-158. [Research Support, Non-U.S. Gov't].
65. Niessner A., Graf S., Nikfardjam M., Speidl W.S., Huber-Beckmann R., Zorn G., et al. Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease-a 13-year follow-up. Thromb Haemost 2003, 90(2):344-350.
66. Pineda J., Marin F., Marco P., Roldan V., Valencia J., Ruiz-Nodar J.M., et al. Premature coronary artery disease in young (age<45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol 2009, 136(2):222-225. [Letter].
67. Pineda J., Marin F., Marco P., Roldan V., Valencia J., Ruiz-Nodar J.M., et al. The prognostic value of biomarkers after a premature myocardial infarction. Int J Cardiol 2010, 143(3):249-254. [Research Support, Non-U.S. Gov't].
68. Redondo M., Carroll V.A., Mauron T., Biasiutti F.D., Binder B.R., Lammle B., et al. Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-alpha2-antiplasmin complex is an independent predictor of coronary re-events. Blood Coagul Fibrinolysis 2001, 12(1):17-24. [Research Support, Non-U.S. Gov't].
69. Thogersen A.M., Nilsson T.K., Weinehall L., Boman K., Eliasson M., Hallmans G., et al. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8years. Blood Coagul Fibrinolysis 2009, 20(5):340-346. [Comparative Study Research Support, Non-U.S. Gov't].
70. Pottinger B.E., Read R.C., Paleolog E.M., Higgins P.G., Pearson J.D. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989, 53(4):387-394.
71. Lip G.Y., Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997, 34(2):255-265. [Research Support, Non-U.S. Gov't Review].
72. Jansson J.H., Nilsson T.K., Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10year follow up of survivors of acute myocardial infarction. Heart 1998, 80(4):334-337.
73. Omicron Hartaigh B., Thomas G.N., Bosch J.A., Hemming K., Pilz S., Loerbroks A., et al. Evaluation of 9 biomarkers for predicting 10-year cardiovascular risk in patients undergoing coronary angiography: findings from the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Int J Cardiol 2013, 168:2609-2615.
74. Hyseni A., Roest M., Braun S.L., Barendrecht A.D., de Groot P.G., Ndrepepa G., et al. Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. Thromb Res 2013, 131(3):198-203. [Research Support, Non-U.S. Gov't].
75. Lee K.W., Lip G.Y., Tayebjee M., Foster W., Blann A.D. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005, 105(2):526-532. [Research Support, Non-U.S. Gov't].
76. Freynhofer M.K., Gruber S.C., Bruno V., Hochtl T., Farhan S., Zaller V., et al. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation. Int J Cardiol 2013, 168:317-325.
77. van Schie M.C., DEM M.P., Dippel D.W., de Groot P.G., Lenting P.J., Leebeek F.W., et al. von Willebrand factor propeptide and the occurrence of a first ischemic stroke. J Thromb Haemost 2010, 8(6):1424-1426.
78. Bath P.M., Blann A., Smith N., Butterworth R.J. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 1998, 9(3-4):155-159.
79. Liu L., Lin Z., Shen Z. Changes of von Willebrand factor and antithrombin III levels in acute stroke: difference between thrombotic and haemorrhagic stroke. Thromb Res 1993, 72(4):353-358.
80. Catto A.J., Carter A.M., Barrett J.H., Bamford J., Rice P.J., Grant P.J. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost 1997, 77(6):1104-1108. [Research Support, Non-U.S. Gov't].
81. Lip G.Y., Blann A.D., Farooqi I.S., Zarifis J., Sagar G., Beevers D.G. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis 2002, 13(4):339-347.
82. van Schie M.C., de Maat M.P., de Groot P.G., Hyseni A., Dippel D.W., Lenting P.J., et al. Active von Willebrand factor and the risk of stroke. Atherosclerosis 2010, 208(2):322-323.
83. Kozuka K., Kohriyama T., Nomura E., Ikeda J., Kajikawa H., Nakamura S. Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype. Atherosclerosis 2002, 161(1):161-168.
84. Hanson E., Jood K., Karlsson S., Nilsson S., Blomstrand C., Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost 2011, 9(2):275-281.
85. Bongers T.N., de Maat M.P., van Goor M.L., Bhagwanbali V., van Vliet H.H., Gomez Garcia E.B., et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006, 37(11):2672-2677.
86. Licata G., Tuttolomondo A., Di Raimondo D., Corrao S., Di Sciacca R., Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost 2009, 101(5):929-937.
87. Uchiyama S., Takeuchi M., Osawa M., Kobayashi I., Maruyama S., Aosaki M., et al. Platelet function tests in thrombotic cerebrovascular disorders. Stroke 1983, 14(4):511-517.
88. Cherian P., Hankey G.J., Eikelboom J.W., Thom J., Baker R.I., McQuillan A., et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003, 34(9):2132-2137.
89. Pinto A., Tuttolomondo A., Casuccio A., Di Raimondo D., Di Sciacca R., Arnao V., et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 2009, 116(10):781-789.
90. Reynolds M.A., Kirchick H.J., Dahlen J.R., Anderberg J.M., McPherson P.H., Nakamura K.K., et al. Early biomarkers of stroke. Clin Chem 2003, 49(10):1733-1739.
91. Stott D.J., Spilg E., Campbell A.M., Rumley A., Mansoor M.A., Lowe G.D. Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis 2001, 12(8):651-657.
92. Wannamethee S.G., Whincup P.H., Lennon L., Rumley A., Lowe G.D. Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor, and risk of incident stroke in older men. Stroke 2012, 43:1206-1211.
93. Gottesman R.F., Cummiskey C., Chambless L., Wu K.K., Aleksic N., Folsom A.R., et al. Hemostatic factors and subclinical brain infarction in a community-based sample: the ARIC study. Cerebrovasc Dis 2009, 28(6):589-594.
94. Knuiman M.W., Folsom A.R., Chambless L.E., Liao D., Wu K.K. Association of hemostatic variables with MRI-detected cerebral abnormalities: the atherosclerosis risk in communities study. Neuroepidemiology 2001, 20(2):96-104.
95. Wieberdink R.G., van Schie M.C., Koudstaal P.J., Hofman A., Witteman J.C., de Maat M.P., et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 2010, 41(10):2151-2156.
96. Johansson L., Jansson J.H., Boman K., Nilsson T.K., Stegmayr B., Hallmans G. Prospective study on soluble thrombomodulin and von Willebrand factor and the risk of ischemic and hemorrhagic stroke. Thromb Haemost 2002, 87(2):211-217.
97. Qizilbash N., Duffy S., Prentice C.R., Boothby M., Warlow C. Von Willebrand factor and risk of ischemic stroke. Neurology 1997, 49(6):1552-1556.
98. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24(1):35-41.
99. Amarenco P., Bogousslavsky J., Caplan L.R., Donnan G.A., Hennerici M.G. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 2009, 27(5):502-508.
100. Ohira T., Shahar E., Chambless L.E., Rosamond W.D., Mosley T.H., Folsom A.R. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke 2006, 37(10):2493-2498.
101. Sonneveld M.A., van Dijk A.C., van den Herik E.G., van Loon J.E., de Lau L.M., van der Lugt A., et al. Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis 2013, 230(2):210-215.
102. Yip H.K., Lai S.L., Lan M.Y., Chang W.N., Liu J.S., Kao Y.F., et al. Time course of platelet activation and von Willebrand factor in patients with non-valvular atrial fibrillation after ischemic stroke. Circ J 2007, 71(3):321-326.
103. Fuster W., Bowie E.J., Lewis J.C., Fass D.N., Owen C.A., Brown A.L. Resistance to arteriosclerosis in pigs with von Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 1978, 61(3):722-730.
104. Fuster V., Fass D.N., Kaye M.P., Josa M., Zinsmeister A.R., Bowie E.J. Arteriosclerosis in normal and von Willebrand pigs: long-term prospective study and aortic transplantation study. Circ Res 1982, 51(5):587-593.
105. Methia N., Andre P., Denis C.V., Economopoulos M., Wagner D.D. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001, 98(5):1424-1428.
106. van Galen K.P., Tuinenburg A., Smeets E.M., Schutgens R.E. Von Willebrand factor deficiency and atherosclerosis. Blood Rev 2012, 26(5):189-196.
107. Nichols T.C., Bellinger D.A., Davis K.E., Koch G.G., Reddick R.L., Read M.S., et al. Porcine von Willebrand disease and atherosclerosis. Influence of polymorphism in apolipoprotein B100 genotype. Am J Pathol 1992, 140(2):403-415. [Research Support, U.S. Gov't, P.H.S.].
108. Bilora F., Zanon E., Casonato A., Bertomoro A., Petrobelli F., Cavraro M., et al. Type IIb von Willebrand disease: role of qualitative defects in atherosclerosis and endothelial dysfunction. Clin Appl Thromb Hemost 2007, 13(4):384-390.
109. Sramek A., Reiber J.H., Gerrits W.B., Rosendaal F.R. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 2001, 104(7):762-767.
110. Federici A.B., Mannucci P.M., Fogato E., Ghidoni P., Matturri L. Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi. Thromb Haemost 1993, 70(5):758-761.
111. Sramek A., Bucciarelli P., Federici A.B., Mannucci P.M., De Rosa V., Castaman G., et al. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 2004, 109(6):740-744.
112. Sanders Y.V., Eikenboom J., de Wee E.M., van der Bom J.G., Cnossen M.H., Degenaar-Dujardin M.E., et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 2013, 11(5):845-854. [Research Support, Non-U.S. Gov't].
113. Furlan M., Robles R., Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996, 87(10):4223-4234.
114. Tsai H.M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996, 87(10):4235-4244.
115. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001, 276(44):41059-41063.
116. Soejima K., Mimura N., Hirashima M., Maeda H., Hamamoto T., Nakagaki T., et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem 2001, 130(4):475-480.
117. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413(6855):488-494.
118. Gao W., Anderson P.J., Sadler J.E. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 2008, 112(5):1713-1719.
119. Uemura M., Tatsumi K., Matsumoto M., Fujimoto M., Matsuyama T., Ishikawa M., et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005, 106(3):922-924.
120. Shang D., Zheng X.W., Niiya M., Zheng X.L. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006, 108(7):2207-2215.
121. Tsai H.M. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007, 21(4):609-632.
122. Kremer Hovinga J.A., Zeerleder S., Kessler P., Romani de Wit T., van Mourik J.A., Hack C.E., et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007, 5(11):2284-2290. [Research Support, Non-U.S. Gov't].
123. Bongers T.N., Emonts M., de Maat M.P., de Groot R., Lisman T., Hazelzet J.A., et al. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thromb Haemost 2010, 103(6):1181-1187.
124. Nguyen T.C., Liu A., Liu L., Ball C., Choi H., May W.S., et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007, 92(1):121-124. [Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov't].
125. Reiter R.A., Varadi K., Turecek P.L., Jilma B., Knobl P. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005, 93(3):554-558. [Research Support, Non-U.S. Gov't].
126. Mannucci P.M., Canciani M.T., Forza I., Lussana F., Lattuada A., Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001, 98(9):2730-2735. [Comparative Study].
127. Gerritsen H.E., Turecek P.L., Schwarz H.P., Lammle B., Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999, 82(5):1386-1389.
128. Whitelock J.L., Nolasco L., Bernardo A., Moake J., Dong J.F., Cruz M.A. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost 2004, 2(3):485-491.
129. Zhou W., Tsai H.M. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost 2004, 91(4):806-811.
130. Kato S., Matsumoto M., Matsuyama T., Isonishi A., Hiura H., Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006, 46(8):1444-1452.
131. Kokame K., Nobe Y., Kokubo Y., Okayama A., Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005, 129(1):93-100. [Evaluation Studies Research Support, Non-U.S. Gov't].
132. Palla R., Valsecchi C., Bajetta M., Spreafico M., De Cristofaro R., Peyvandi F. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thromb Haemost 2011, 105(2):381-385.
133. Tripodi A., Peyvandi F., Chantarangkul V., Palla R., Afrasiabi A., Canciani M.T., et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008, 6(9):1534-1541.
134. Furlan M., Lammle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin Haematol 1998, 11(2):509-514.
135. Kokame K., Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004, 41(1):34-40.
136. Licht C., Stapenhorst L., Simon T., Budde U., Schneppenheim R., Hoppe B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int 2004, 66(3):955-958.
137. Noris M., Bucchioni S., Galbusera M., Donadelli R., Bresin E., Castelletti F., et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005, 16(5):1177-1183.
138. Schiviz A., Wuersch K., Piskernik C., Dietrich B., Hoellriegl W., Rottensteiner H., et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012, 119(25):6128-6135.
139. Plaimauer B., Kremer Hovinga J.A., Juno C., Wolfsegger M.J., Skalicky S., Schmidt M., et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011, 9(5):936-944.
140. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease. Am J Med 1952, 13(5):567-569.
141. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339(22):1585-1594.
142. Yoo G., Blomback M., Schenck-Gustafsson K., He S. Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation. Br J Haematol 2003, 121(1):123-129.
143. He S., Cao H., Magnusson C.G., Eriksson-Berg M., Mehrkash M., Schenck-Gustafsson K., et al. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein. Thromb Res 2001, 103(3):241-248.
144. Lambers M., Goldenberg N.A., Kenet G., Kirkham F.J., Manner D., Bernard T., et al. Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study. Ann Neurol 2013, 73(1):58-64.
145. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22(8):983-988.
146. Uemura T., Kaikita K., Yamabe H., Soejima K., Matsukawa M., Fuchigami S., et al. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. Thromb Res 2009, 124(1):28-32.
147. Ammash N., Konik E.A., McBane R.D., Chen D., Tange J.I., Grill D.E., et al. Left atrial blood stasis and Von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation. Arterioscler Thromb Vasc Biol 2011, 31(11):2760-2766.
148. Gandhi C., Khan M.M., Lentz S.R., Chauhan A.K. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood 2012, 119(10):2385-2391.
149. Jin S.Y., Tohyama J., Bauer R.C., Cao N.N., Rader D.J., Zheng X.L. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler Thromb Vasc Biol 2012, 32(8):1817-1823.
150. Zhao B.Q., Chauhan A.K., Canault M., Patten I.S., Yang J.J., Dockal M., et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009, 114(15):3329-3334.
151. Fujioka M., Hayakawa K., Mishima K., Kunizawa A., Irie K., Higuchi S., et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010, 115(8):1650-1653.
152. De Meyer S.F., Savchenko A.S., Haas M.S., Schatzberg D., Carroll M.C., Schiviz A., et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 2012, 120(26):5217-5223.
153. Gandhi C., Motto D.G., Jensen M., Lentz S.R., Chauhan A.K. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. Blood 2012, 120(26):5224-5230.
154. Khan M.M., Motto D.G., Lentz S.R., Chauhan A.K. ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost 2012, 10(8):1665-1671.
155. Doi M., Matsui H., Takeda H., Saito Y., Takeda M., Matsunari Y., et al. ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction. Thromb Haemost 2012, 108(6):1236-1238.
156. Gandhi C., Ahmad A., Wilson K.M., Chauhan A.K. ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. J Thromb Haemost 2014, 12:255-260.
157. Wu O., Bayoumi N., Vickers M.A., Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008, 6(1):62-69. [Meta-Analysis].
158. Whincup P.H., Cook D.G., Phillips A.N., Shaper A.G. ABO blood group and ischaemic heart disease in British men. BMJ 1990, 300(6741):1679-1682. [Research Support, Non-U.S. Gov't].
159. van Schie M.C., van Loon J.E., de Maat M.P., Leebeek F.W. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost 2011, 9(5):899-908. [Research Support, Non-U.S. Gov't Review].
160. Van Schie M.C., Wieberdink R.G., Koudstaal P.J., Hofman A., Ikram M.A., Witteman J.C., et al. Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study. J Thromb Haemost 2012, 10(4):550-556.
161. van Loon J.E., Kavousi M., Leebeek F.W., Felix J.F., Hofman A., Witteman J.C., et al. von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population. J Thromb Haemost 2012, 10(7):1262-1269. [Research Support, Non-U.S. Gov't].